
  
    
      
        PRESENTATION_NNP of_IN CASE_NN
        A_DT 38_CD -_: y-old_JJ woman_NN with_IN Down_IN syndrome_NN was_VBD admitted_VBN to_TO hospital_NN for_IN investigation_NN of_IN a_DT 6_CD -_: mo_NN
        history_NN of_IN anorexia_NN and_CC weight_NN loss_NN of_IN 40_CD lbs_NNS ._. Six_CD months_NNS prior_RB to_TO admission_NN ,_, her_PRP$ weight_NN
        was_VBD 175_CD lbs_NNS ,_, and_CC her_PRP$ body_NN mass_NN index_NN was_VBD 36_CD ._. On_IN admission_NN ,_, her_PRP$ complete_JJ blood_NN count_NN was_VBD
        normal_JJ ,_, but_CC over_IN a_DT 2_CD -_: wk_NN period_NN she_PRP developed_VBD acute_JJ pancytopenia_NN (_( Figure_NN 1_LS )_) ._. During_IN this_DT
        acute_JJ episode_NN ,_, her_PRP$ lowest_JJS hematological_JJ parameters_NNS were_VBD as_IN follows_VBZ :_: hemoglobin_NN (_( Hb_NNP )_) ,_, 80_CD g_SYM /_NN l_NN
        (_( normal_JJ range_NN 120_CD –_NN 160_CD g_SYM /_NN l_NN )_) ;_: mean_VB cell_NN volume_NN (_( MCV_NNP )_) ,_, 121_CD fl_NN (_( 80_CD –_NN 95_CD fl_NN )_) ;_: white_JJ blood_NN cell_NN
        count_NN (_( WBC_NNP )_) ,_, 2_CD ._. 9_CD ×_NN 10_CD
        6_CD /_NN l_NN (_( 4_CD ._. 8_CD –_NN 10_CD ._. 8_CD ×_NN 10_CD
        6_CD /_NN l_NN )_) ;_: absolute_JJ neutrophil_NN count_NN ,_, 1_CD ._. 1_CD ×_NN 10_CD
        6_CD /_NN l_NN (_( 1_CD ._. 5_LS –_NN 6_CD ._. 2_LS ×_NN 10_CD
        6_CD /_NN l_NN )_) ;_: and_CC platelet_NN count_NN ,_, 76_CD ×_NN 10_CD
        6_CD /_NN l_NN (_( 150_CD –_NN 350_CD ×_NN 10_CD
        6_CD /_NN l_NN )_) ._.
        She_PRP had_VBD been_VBN taking_VBG carbamazepine_NN for_IN 17_CD y_NN and_CC sodium_NN valproate_NN for_IN 13_CD y_NN for_IN a_DT mixed_JJ
        seizure_NN disorder_NN ._. At_IN age_NN 22_CD y_NN ,_, before_IN starting_VBG any_DT anticonvulsants_NNS ,_, her_PRP$ baseline_NN
        hematological_JJ parameters_NNS were_VBD as_IN follows_VBZ :_: Hb_NNP ,_, 123_CD g_SYM /_NN l_NN ;_: MCV_NNP ,_, 106_CD fl_NN ;_: platelets_NNS ,_, 296_CD ×_NN 10_CD
        6_CD /_NN l_NN ;_: and_CC WBC_NNP ,_, 10_CD ._. 7_CD ×_NN 10_CD
        6_CD /_NN l_NN ._. After_IN starting_VBG carbamazepine_NN ,_, her_PRP$ WBC_NNP dropped_VBD to_TO 4_CD ._. 5_CD –_NN 5_CD ._. 5_LS ×_NN 10_CD
        6_CD /_NN l_NN ,_, and_CC her_PRP$ absolute_JJ neutrophil_NN count_NN dropped_VBD from_IN 9_CD ×_NN 10_CD
        6_CD /_NN l_NN to_TO about_IN 2_CD ._. 5_CD ×_NN 10_CD
        6_CD /_NN l_NN ._. When_WRB the_DT sodium_NN valproate_NN was_VBD added_VBN ,_, her_PRP$ MCV_NNP increased_VBD to_TO 112_CD fl_NN ,_,
        her_PRP$ platelet_NN count_NN fell_VBD to_TO 100_CD –_NN 150_CD ×_NN 10_CD
        6_CD /_NN l_NN ,_, and_CC her_PRP$ Hb_NNP dropped_VBD to_TO 110_CD –_NN 120_CD g_SYM /_NN l_NN ._.
        The_DT patient_NN 's_POS other_JJ medications_NNS on_IN admission_NN were_VBD carnitine_NN and_CC low-dose_JJ L-_NNP thyroxine_NN for_IN
        hypothyroidism_NN ;_: she_PRP had_VBD been_VBN taking_VBG both_DT for_IN several_JJ years_NNS ._. She_PRP had_VBD not_RB been_VBN recently_RB
        exposed_VBN to_TO any_DT new_JJ medications_NNS ,_, environmental_JJ toxins_NNS ,_, or_CC over-the-counter_JJ dietary_JJ
        supplements_NNS ._. There_EX was_VBD no_DT family_NN history_NN of_IN aplastic_JJ anemia_NN ._. The_DT patient_NN lived_VBD at_IN home_NN with_IN
        her_PRP$ mother_NN ,_, who_WP cares_VBZ for_IN her_PRP$ and_CC has_VBZ legal_JJ guardianship_NN ._.
        A_DT bone_NN marrow_NN biopsy_NN (_( Figure_NN 2_LS )_) showed_VBD a_DT hypocellular_NN bone_NN marrow_NN with_IN a_DT normal_JJ
        myeloid_NN :_: erythroid_NN ratio_NN and_CC no_DT malignant_JJ cells_NNS or_CC megaloblastic_JJ changes_NNS ._. Cytogenetic_NNP study_NN
        showed_VBD a_DT Robertsonian_NNP (_( i_NNP ._. e_SYM ._. ,_, of_IN the_DT whole_JJ arms_NNS )_) translocation_NN of_IN Chromosome_NNP 14_CD and_CC 21_CD
        involving_VBG the_DT long_JJ arm_NN of_IN Chromosome_NNP 21_CD ._. Except_IN for_IN mild_JJ adrenal_NN insufficiency_NN noted_VBD on_IN an_DT
        adrenocorticotropic_JJ hormone_NN stimulation_NN test_NN ,_, all_DT her_PRP$ tests_NNS ,_, including_VBG viral_JJ and_CC
        immunological_JJ investigations_NNS to_TO identify_VB known_VBN causes_NNS of_IN aplastic_JJ anemia_NN ,_, were_VBD negative_JJ ._.
        The_DT patient_NN 's_POS thyroid_NN function_NN tests_NNS were_VBD normal_JJ ._. She_PRP was_VBD started_VBN on_IN low-dose_JJ
        hydrocortisone_NN for_IN her_PRP$ adrenal_NN insufficiency_NN and_CC megestrol_NN acetate_NN to_TO increase_VB her_PRP$
        appetite_NN ._.
        The_DT patient_NN 's_POS carbamazepine_NN was_VBD discontinued_VBN ._. Within_IN 10_CD d_SYM ,_, her_PRP$ WBC_NNP had_VBD risen_VBN to_TO 6_CD ._. 7_CD ×_NN 10_CD
        6_CD /_NN l_NN and_CC her_PRP$ platelet_NN count_NN to_TO 248_CD ×_NN 10_CD
        6_CD /_NN l_NN ._. Serial_JJ complete_JJ blood_NN counts_VBZ showed_VBN worsening_VBG anemia_NN over_IN the_DT next_JJ
        15_CD wk_NN ,_, requiring_VBG two_CD packed_VBN red_JJ blood_NN cell_NN transfusions_NNS at_IN week_NN 6_CD and_CC week_NN 14_CD ,_, when_WRB her_PRP$ Hb_NNP
        was_VBD 31_CD and_CC 53_CD g_SYM /_NN l_NN ,_, respectively_RB ._. Throughout_IN this_DT period_NN ,_, her_PRP$ reticulocyte_NN count_NN was_VBD low_JJ ,_, at_IN
        about_IN 0_CD ._. 18_CD %_NN (_( normal_JJ range_NN 0_CD ._. 5_CD %_NN –_NN 2_CD %_NN )_) ,_, while_IN her_PRP$ WBC_NNP and_CC platelet_NN count_NN were_VBD normal_JJ ._. We_PRP made_VBD a_DT
        diagnosis_NN of_IN pure_JJ red_JJ cell_NN aplasia_NN (_( PRCA_NNP )_) ._. A_DT second_JJ bone_NN marrow_NN biopsy_NN under_IN minimally_RB
        conscious_JJ sedation_NN was_VBD unsuccessful_JJ ,_, and_CC the_DT patient_NN declined_VBD further_JJ attempts_NNS ._. After_IN the_DT
        first_JJ transfusion_NN she_PRP was_VBD started_VBN on_IN prednisone_NN and_CC erythropoietin_NN for_IN her_PRP$ PRCA_NNP ._. Meanwhile_RB ,_,
        because_IN of_IN her_PRP$ worsening_VBG seizures_NNS ,_, we_PRP increased_VBD her_PRP$ sodium_NN valproate_NN dose_NN ,_, increasing_VBG her_PRP$
        serum_NN valproate_NN level_NN from_IN 70_CD mcg_NN /_NN ml_NN to_TO 110_CD mcg_NN /_NN ml_NN ._. After_IN the_DT second_JJ transfusion_NN ,_, we_PRP
        discontinued_VBN her_PRP$ sodium_NN valproate_NN and_CC started_VBD her_PRP on_IN clonazepam_NN and_CC oxcarbazepine_NN as_IN
        alternative_JJ anticonvulsants_NNS ._.
        The_DT patient_NN had_VBD a_DT brisk_JJ reticulocyte_NN response_NN ._. Her_PRP$ reticulocyte_NN count_NN rose_VBD from_IN 0_CD ._. 36_CD %_NN to_TO
        0_CD ._. 78_CD %_NN in_IN the_DT second_JJ week_NN and_CC to_TO 6_CD ._. 61_CD %_NN in_IN the_DT fourth_JJ week_NN after_IN stopping_VBG the_DT valproate_NN ._. Six_CD
        weeks_NNS after_IN stopping_VBG the_DT drug_NN ,_, her_PRP$ Hb_NNP was_VBD 125_CD g_SYM /_NN l_NN and_CC her_PRP$ MCV_NNP was_VBD 106_CD fl_NN ,_, suggesting_VBG
        replacement_NN of_IN transfused_JJ red_JJ blood_NN cells_NNS with_IN newly_RB formed_VBN red_JJ blood_NN cells_NNS (_( which_WDT have_VBP a_DT
        higher_JJR MCV_NNP than_IN older_JJR transfused_JJ cells_NNS )_) ._. Over_IN the_DT next_JJ 30_CD mo_NN of_IN follow-up_JJ ,_, she_PRP had_VBD no_DT
        relapse_NN of_IN her_PRP$ aplastic_JJ anemia_NN ._.
        We_PRP were_VBD unable_JJ to_TO identify_VB a_DT specific_JJ cause_NN for_IN the_DT patient_NN 's_POS anorexia_NN and_CC weight_NN loss_NN ._.
        We_PRP found_VBD no_DT evidence_NN of_IN malignancy_NN on_IN admission_NN or_CC subsequent_JJ follow-up_JJ ._. Within_IN 1_CD wk_NN of_IN
        stopping_VBG her_PRP$ sodium_NN valproate_NN ,_, her_PRP$ appetite_NN improved_VBN and_CC she_PRP put_VBP on_IN 15_CD lbs_NNS over_IN the_DT next_JJ 6_CD
        wk_NN ._. By_IN the_DT fourth_JJ month_NN after_IN stopping_VBG the_DT drug_NN ,_, she_PRP had_VBD gained_VBN 45_CD lbs_NNS ._.
        We_PRP last_RB saw_VBD the_DT patient_NN in_IN August_NNP 2004_CD ._. Her_PRP$ seizure_NN control_NN had_VBD worsened_VBN ,_, and_CC she_PRP had_VBD
        developed_VBN signs_NNS of_IN early_JJ dementia_NN ._. Her_PRP$ current_JJ anticonvulsants_NNS are_VBP clonazepam_NN ,_,
        oxcarbazepine_NN ,_, and_CC zonisamide_NN ,_, and_CC she_PRP continues_VBZ taking_VBG synthroid_NN ._. Her_PRP$ last_JJ complete_JJ blood_NN
        count_NN was_VBD stable_JJ :_: WBC_NNP ,_, 6_CD ._. 4_CD ×_NN 10_CD
        6_CD /_NN l_NN ;_: Hb_NNP ,_, 147_CD g_SYM /_NN l_NN ;_: MCV_NNP ,_, 104_CD ._. 9_CD fl_NN ;_: and_CC platelets_NNS ,_, 262_CD ×_NN 10_CD
        6_CD /_NN l_NN ._.
      
      
        Discussion_NNP
        Sodium_NNP valproate_NN and_CC carbamazepine_NN are_VBP associated_VBN with_IN rare_JJ but_CC potentially_RB lethal_JJ
        hematological_JJ complications_NNS ._. There_EX are_VBP five_CD case_NN reports_NNS of_IN PRCA_NNP shortly_RB after_IN initiation_NN
        of_IN sodium_NN valproate_NN ,_, with_IN the_DT longest_JJS interval_NN between_IN the_DT initiation_NN of_IN therapy_NN and_CC the_DT
        onset_NN of_IN aplasia_NN being_VBG 2_CD y_NN [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ]_NN ._. Acute_NNP bone_NN marrow_NN suppression_NN with_IN leucopenia_NN and_CC
        thrombocytopenia_NN associated_VBN with_IN carbamazepine_NN most_RBS often_RB occur_VB within_IN 4_CD mo_NN of_IN starting_VBG
        treatment_NN [_NN 6_CD ,_, 7_CD ]_NN ._. As_RB far_RB as_IN we_PRP know_VBP ,_, our_PRP$ case_NN report_NN is_VBZ unique_JJ in_IN that_IN the_DT patient_NN developed_VBD
        acute_JJ bone_NN marrow_NN suppression_NN and_CC PRCA_NNP after_IN 17_CD y_NN of_IN carbamazepine_NN and_CC 13_CD y_NN of_IN sodium_NN
        valproate_NN therapy_NN ._.
        Our_PRP$ investigations_NNS ruled_VBD out_IN most_JJS of_IN the_DT known_VBN causes_NNS of_IN acute_JJ bone_NN marrow_NN suppression_NN ,_,
        making_VBG the_DT anticonvulsants_NNS the_DT most_RBS likely_JJ cause_NN ._. Malnutrition_NNP was_VBD an_DT unlikely_JJ cause_NN :_: her_PRP$
        WBC_NNP and_CC platelet_NN counts_VBZ had_VBN recovered_VBN before_IN any_DT increase_NN in_IN appetite_NN or_CC weight_NN gain_NN ;_: her_PRP$
        body_NN mass_NN index_NN was_VBD normal_JJ despite_IN her_PRP$ weight_NN loss_NN ;_: and_CC her_PRP$ bone_NN marrow_NN iron_NN stores_NNS were_VBD
        adequate_JJ and_CC her_PRP$ serum_NN folate_NN and_CC vitamin_NN B_NNP 12_CD levels_NNS were_VBD high_JJ ,_, suggesting_VBG adequate_JJ
        nutrient_NN supply_NN ._.
        We_PRP considered_VBD and_CC rejected_VBN the_DT possibility_NN of_IN Down_IN syndrome–associated_JJ aplastic_JJ anemia_NN ._.
        There_EX have_VBP been_VBN six_CD case_NN reports_NNS of_IN this_DT condition_NN ,_, and_CC in_IN all_DT cases_NNS it_PRP occurred_VBD in_IN young_JJ
        children_NNS ,_, suggesting_VBG a_DT genetic_JJ predisposition_NN [_NN 8_CD ]_NN ._. Half_NN of_IN these_DT patients_NNS died_VBD ,_, and_CC half_NN
        responded_VBD partially_RB to_TO androgenic_JJ steroids_NNS ._. Our_PRP$ patient_NN was_VBD an_DT adult_NN ,_, and_CC her_PRP$ bone_NN marrow_NN
        had_VBD responded_VBN to_TO the_DT withdrawal_NN of_IN her_PRP$ anticonvulsants_NNS and_CC not_RB to_TO the_DT administration_NN of_IN
        androgenic_JJ steroid_NN ._. She_PRP had_VBD failed_VBN to_TO respond_VB to_TO a_DT 6_CD -_: wk_NN course_NN of_IN high-dose_JJ non-androgenic_JJ
        steroid_NN and_CC erythropoietin_NN ._. Furthermore_RB ,_, our_PRP$ patient_NN did_VBD not_RB have_VB a_DT relapse_NN of_IN her_PRP$ aplastic_JJ
        anemia_NN in_IN 30_CD mo_NN of_IN follow-up_JJ ,_, suggesting_VBG a_DT lack_NN of_IN genetic_JJ disposition_NN ._.
        The_DT brisk_JJ return_NN of_IN her_PRP$ WBC_NNP and_CC platelet_NN counts_VBZ upon_IN discontinuing_VBG carbamazepine_NN ,_, and_CC
        her_PRP$ brisk_JJ reticulocytosis_NNS upon_IN discontinuing_VBG sodium_NN valproate_NN ,_, were_VBD both_DT consistent_JJ with_IN
        previous_JJ reports_NNS of_IN hematological_JJ toxicity_NN due_JJ to_TO these_DT drugs_NNS [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._. What_WP was_VBD
        unusual_JJ in_IN our_PRP$ case_NN was_VBD the_DT extremely_RB late_JJ onset_NN of_IN bone_NN marrow_NN suppression_NN after_IN
        initiation_NN of_IN drug_NN therapy_NN ._. The_DT persistent_JJ suppression_NN of_IN erythropoietic_JJ elements_NNS for_IN 15_CD wk_NN
        after_IN stopping_VBG the_DT carbamazepine_NN was_VBD unlikely_JJ to_TO be_VB due_JJ to_TO persistent_JJ residual_JJ marrow_NN
        suppression_NN by_IN carbamazepine_NN ,_, since_IN carbamazepine-induced_JJ PRCA_NNP responds_VBZ quickly_RB (_( within_IN 1_CD –_NN 2_CD
        wk_NN )_) to_TO stopping_VBG the_DT drug_NN [_NN 6_CD ,_, 9_CD ]_NN ._. We_PRP believe_VBP that_IN the_DT continued_VBN use_NN of_IN sodium_NN valproate_NN ,_,
        after_IN stopping_VBG the_DT carbamazepine_NN ,_, caused_VBD the_DT persistent_JJ suppression_NN of_IN erythropoietic_JJ
        elements_NNS ._.
        We_PRP found_VBD no_DT cause_NN for_IN the_DT patient_NN 's_POS anorexia_NN and_CC weight_NN loss_NN ,_, but_CC her_PRP$ appetite_NN returned_VBD
        and_CC she_PRP gained_VBD weight_NN after_IN stopping_VBG the_DT sodium_NN valproate_NN ._. There_EX is_VBZ a_DT known_VBN association_NN
        between_IN this_DT drug_NN and_CC anorexia_NN [_NN 10_CD ]_NN ._.
      
    
  
